Subscribe

Advertisement

ETS Methods in Head & Neck Reconstruction

Skin Dose-Volume Impact on ARD in HN RT

The study aimed to investigate novel dosimetric predictors of ARD in head and neck radiotherapy, examining clinician-rated and PRO. Researchers noticed significant associations between skin dose-volume parameters correlated with acute radiation dermatitis, emphasizing the need to minimize skin exposure; further investigation is ongoing. Acute radiation dermatitis (ARD) is a common side effect of […]...

Advertisement

Advertisement

Advertisement

SELECT ONCOLOGY JOURNAL ARTICLES

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial

Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase …

BMJ Journals

Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma

Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma

Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …

BMJ Journals

1397 CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)

1397 CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)

Background Squamous non-small cell lung cancer (SQ-NSCLC) is the 2nd most common type of lung cancer. Given the paucity of actionable oncogene drivers, and lack of efficacy from multiple therapies in the Lung-MAP trial, there is …

BMJ Journals